Global Peyronie’s Disease Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Peyronie’s Disease Treatment Market Analysis

The Peyronie’s disease treatment market is growing steadily, driven by increasing awareness of the condition and advancements in medical technologies. Peyronie’s disease (PD) is a connective tissue disorder characterized by the formation of fibrous plaques in the penis, leading to curvature, pain, and potential erectile dysfunction. It is estimated to affect approximately 1 in 10 men, particularly in middle and older age groups, making it a significant men’s health issue. Recent advancements have improved treatment options, ranging from minimally invasive therapies to advanced surgical procedures. For instance, collagenase clostridium histolyticum (XIAFLEX) remains the only FDA-approved nonsurgical treatment, offering patients a targeted, effective approach to manage plaque and penile curvature. The integration of digital health tools, such as self-assessment apps and telemedicine platforms, has further enhanced patient engagement and access to care. In addition, innovations such as shockwave therapy and next-generation devices such as VerticaPlus, which combine treatment with cloud-based mobile applications for personalized feedback, represent a shift towards patient-centric solutions. As awareness campaigns and product launches increase, the Peyronie’s disease treatment market is expected to witness robust growth, benefiting both patients and healthcare providers.

Peyronie’s Disease Treatment Market Size

The global peyronie’s disease treatment market size was valued at USD 448.77 million in 2024 and is projected to reach USD 668.11 million by 2032, with a CAGR of 5.10% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Peyronie’s Disease Treatment Market Trends

“Increasing Integration of Digital Health Tools”

The Peyronie’s disease treatment Market is experiencing significant growth, driven by increasing awareness and technological advancements. A key trend shaping the market is the integration of digital health tools to improve diagnosis and treatment outcomes. For instance, Endo International plc, in collaboration with the Sexual Medicine Society of North America, launched the Peyronie’s Self-Assessment App, enabling men to evaluate their symptoms conveniently. This innovation reflects a broader shift towards patient-centric solutions that leverage technology for enhanced accessibility. In addition, the growing adoption of nonsurgical treatments such as XIAFLEX (collagenase clostridium histolyticum), the only FDA-approved therapy for Peyronie’s disease, underscores the market's focus on minimally invasive options. The combination of digital tools with advanced therapies ensures timely intervention, improving patient outcomes. As awareness campaigns and education initiatives continue to expand, the Peyronie’s disease treatment market is poised for robust growth, addressing the unmet needs of men’s health effectively.

Report Scope and Peyronie’s Disease Treatment Market Segmentation         

Peyronie’s Disease Treatment Market Definition

Peyronie’s Disease Treatment refers to medical and therapeutic interventions aimed at managing Peyronie’s disease, a connective tissue disorder characterized by the formation of fibrous plaques in the penile tissue. This condition can cause penile curvature, pain, and functional issues such as erectile dysfunction. Treatments for Peyronie’s disease range from non-invasive options, such as oral medications and injectable therapies (collagenase clostridium histolyticum/XIAFLEX), to physical therapies such as shockwave treatment and surgical procedures for severe cases.

Peyronie’s Disease Treatment Market Dynamics

Drivers

• Growing Awareness of Peyronie’s Disease

Growing awareness of Peyronie’s disease, particularly through educational campaigns and media initiatives, plays a significant role in encouraging more men to seek treatment, which directly contributes to the expansion of the market. As awareness around the condition increases, more individuals are becoming informed about its symptoms, risks, and available therapies. For instance, in 2024, Endo International plc launched the PD Pool Hall video series to educate the public on Peyronie’s disease, highlighting its impact and the importance of treatment. Such campaigns help reduce the stigma surrounding the condition and promote early intervention, which is crucial for effective treatment. This heightened awareness drives men to consult healthcare providers and creates a demand for a wider range of treatments, from oral medications to nonsurgical options such as XIAFLEX. As more men are diagnosed and seek care, the Peyronie’s disease treatment market is seeing a marked increase in growth, making awareness a key market driver.

• Rising Focus on Men’s Health

The rising focus on men’s health, particularly in areas related to sexual well-being, is becoming a key driver for investments in the Peyronie’s disease treatment market. As society places more emphasis on addressing health issues affecting men, there is growing recognition of conditions such as Peyronie’s disease, which impacts sexual health and quality of life. This shift is encouraging pharmaceutical companies to develop innovative treatments and expand their product portfolios. For instance, the launch of XIAFLEX as a nonsurgical treatment for Peyronie’s disease reflects the increasing attention being given to non-invasive therapies for men’s sexual health. Furthermore, companies are investing in educational initiatives and digital health tools, such as self-assessment apps, to engage men in early diagnosis and treatment. As men become more open to discussing and addressing sexual health concerns, there is a surge in demand for effective therapies, driving growth in the market and attracting further investments from both healthcare providers and pharmaceutical companies.

Opportunities

• Increasing Technological advancements

Technological advancements in the Peyronie’s disease treatment market present significant opportunities for growth by making treatment more accessible and effective. Innovations such as XIAFLEX (collagenase clostridium histolyticum), the first FDA-approved injectable therapy for Peyronie’s disease, have revolutionized the management of the condition by offering a nonsurgical alternative to traditional treatments. This injectable therapy targets the fibrous plaques that cause penile curvature, providing patients with a less invasive solution with proven efficacy. In addition, the development of digital health tools, such as mobile apps for self-assessment, enhances patient engagement and facilitates early diagnosis. For instance, the Peyronie’s Self-Assessment App launched by Endo International in collaboration with the Sexual Medicine Society of North America, allows men to evaluate their symptoms and seek appropriate medical care. These technological advancements improve treatment outcomes and create market opportunities by expanding access to care, encouraging early intervention, and providing patients with more personalized treatment options.

• Increasing Preference for Minimally Invasive Treatments

The preference for minimally invasive treatments, such as shockwave therapy and injectable therapies, is driving significant growth in the Peyronie’s disease treatment market by offering patients effective alternatives to traditional surgical options. Shockwave therapy, for instance, uses sound waves to promote healing and reduce plaque formation, providing a non-invasive and relatively painless option for men seeking relief from Peyronie’s disease. Similarly, XIAFLEX, an injectable collagenase treatment, offers a non-surgical way to break down the fibrous tissue causing penile curvature. These therapies are particularly appealing as they involve less downtime, fewer risks, and quicker recovery compared to surgery. As a result, there is an increasing demand for these alternatives, making the market more accessible to a broader patient population. This shift toward minimally invasive options presents a significant market opportunity, as healthcare providers are more likely to adopt these treatments, and patients are more inclined to pursue them due to their convenience and effectiveness.

Restraints/Challenges

• High Treatment Costs

High treatment costs represent a significant market challenge in the Peyronie’s Disease treatment space, limiting access to care for many patients, particularly those without adequate insurance coverage. For instance, the FDA-approved drug Xiaflex, one of the most well-known treatments for Peyronie’s Disease, can be prohibitively expensive, making it unaffordable for a large portion of the population, especially in regions with high out-of-pocket healthcare expenses or where insurance coverage is insufficient. Furthermore, many insurance companies do not cover the cost of treatment for Peyronie’s Disease, leaving patients to bear the financial burden themselves. This high cost deters patients from pursuing treatment and affects the overall adoption of new therapies in the market, as fewer individuals can afford them. Consequently, this cost barrier hinders the growth and penetration of treatments, presenting a major obstacle to the expansion of the Peyronie’s Disease treatment market.

• Stigma Surrounding Peyronie’s Disease

The stigma surrounding Peyronie’s Disease, coupled with its significant psychological impact, is a major challenge in the treatment market. Many men feel embarrassed or self-conscious about their condition, as it affects their sexual health and self-esteem, leading to reluctance in seeking medical help. This emotional burden is often compounded by anxiety, depression, and relationship difficulties, further discouraging patients from addressing the issue. For instance, a study found that men with Peyronie’s Disease often experience severe psychological distress, with some reporting that their condition affects their intimacy and overall quality of life. The stigma also extends to healthcare providers, as many may not initiate discussions about sexual health unless prompted, which can result in delayed diagnosis and treatment. This reluctance to seek help diminishes the potential patient pool for treatment providers, stunting market growth. In addition, the need for specialized counseling or psychological support to address the emotional and relational impacts of the disease adds complexity to the treatment process, increasing overall costs and discouraging more patients from engaging with available therapies.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Peyronie’s Disease Treatment Market Scope

The market is segmented on the basis of therapy type, treatment, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapy Type

• Radiation Therapy
• Shockwave Therapy

Treatment

• Drugs
• Surgery

Route of Administration

• Oral
• Injectable
• Topical

End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Peyronie’s Disease Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, therapy type, treatment, route of administration, end users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the Peyronie’s disease treatment market, driven by a growing prevalence of the condition. The region benefits from advanced healthcare infrastructure, making treatment more accessible. Additionally, heightened awareness about Peyronie’s disease and its available therapies is contributing to increasing diagnosis and treatment rates. These factors are expected to accelerate the market's growth in North America throughout the forecast period.

Asia-Pacific region is expected to experience highest growth in the Peyronie’s disease treatment market, driven by a rising incidence of the condition. Additionally, changing lifestyle factors, such as increased stress and poor dietary habits, are contributing to the growing prevalence of Peyronie’s disease in this area. As awareness of the condition improves and access to healthcare expands, the demand for treatment options is set to rise. This combination of factors is anticipated to fuel significant market growth in the Asia-Pacific region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Peyronie’s Disease Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Peyronie’s Disease Treatment Market Leaders Operating in the Market Are:

• Endo, Inc. (U.S.)
• Biodexa Pharmaceuticals PLC (U.K.)
• Teva Pharmaceutical Industries Ltd (Israel)
• Viatris Inc. (U.S.)
• Mayne Pharma Group Limited (Australia)
• Zydus Group (India)
• Sun Pharmaceutical Industries Ltd (India)
• GLENMARK PHARMACEUTICALS LTD. (India)
• Amneal Pharmaceuticals LLC (U.S.)
• Pfizer Inc. (U.S.)

Latest Developments in Peyronie’s Disease Treatment Market

• In June 2024, Ohh-Med Medical introduced the next-generation VerticaPlus, a cutting-edge interventional urology and men's health device with a cloud-based mobile app. This advanced version enhances the original Vertica with features such as personalized treatment parameters, guided tutorials, real-time feedback, and a robust mobile interface that acts as a 'personal coach' during treatment
• In November 2024, Endo International plc launched a branded video series, PD Pool Hall, to educate men about Peyronie's disease (PD). The series raises awareness about this condition, estimated to affect 1 in 10 men in the U.S., which can cause a curvature deformity of the penis when erect
• In October 2022, Endo International plc, in collaboration with the Sexual Medicine Society of North America (SMSNA), launched the Peyronie's Self-Assessment application. Available on the App Store and Google Play, the app helps men evaluate their condition, characterized by plaque formation that may result in a penile curvature deformity
• In October 2021, Endo International plc released its first-ever XIAFLEX (collagenase clostridium histolyticum) television commercial, titled Bent Carrot. The ad highlights XIAFLEX as the only nonsurgical FDA-approved treatment for Peyronie's disease and encourages men to seek medical treatment for the condition, which involves fibrous scar tissue (plaque) leading to penile curvature

SKU-48014